BioCentury
ARTICLE | Company News

Taxus Cardium, Shenzhen Qianhai Taxus Insdustry Capital Management deal

May 25, 2015 7:00 AM UTC

Taxus Cardium granted Shenzhen the first right to negotiate for an exclusive license to develop and commercialize three Taxus products in Asian countries. The products include Generx alferminogene tadenovec, an adenoviral vector carrying the fibroblast growth factor 4 (FGF4) gene, which is in Phase III development to treat cardiac microvascular insufficiency in patients with myocardial ischemia and symptomatic chronic stable pectoris due to coronary microvascular dysfunction; Excellagen, a topical collagen-based gel matrix is marketed in the U.S. for advanced wound healing; and LifeAgain, a medical data analytics technology platform. Shenzhen will be responsible for regulatory activities and commercialization. ...